Novantrone® (mitoxantrone for injection concentrate)

OSI markets and promotes Novantrone for the approved oncology indications in the U.S. pursuant to a co-promotion agreement with an affiliate of Merck Serono, S.A. signed in March 2003.

Novantrone is also approved for certain advanced forms of multiple sclerosis (MS), marketed by EMD Serono, Inc.

• www.novantrone.com

For more information on Novantrone®, call 1-800-572-1932.